Spinal muscular atrophy



All types of SMA are diagnosed through a blood test (genetic testing) to determine whether both copies of the SMN1 gene have a fault (deletion) responsible for SMA. A positive test will result in a diagnosis of 5q SMA.

Counting the number of SMN2 genes can be a helpful indicator for the prognosis of the condition (how it will develop). It can, therefore, guide the best care and management. The number of SMN2 copies can also be a factor in entry criteria for clinical trials.

Link to page 14-15 of the Guide to the 2017 International Standards of Care for SMA

Last modified
03 March 2020
New study!

Impact of neuromuscular diseases on education and working opportunities of patients and carers